(SR) group by morphology. In SR patients, FCM-MRD andGATA1-MRD after induction were positive in 5/65 and 7/59 patients, respectively. Three-year event-free survival (EFS) and overall survival (OS) rates were 95.0% and 96.7% in the FCM-MRD-negative population, and 60.0% and 80.0% in...
With current intensive approaches, the complete remission (CR) rates are up to 70%, making conventional evaluations of response quite useless. More sensitive tools are mandatory. Two techniques may help investigators to reach this goal, flow cytometry (FCM) and NGS. We applied both techniques to...
inhibitor (TKI) treatment guided by circulating tumor DNA (ctDNA) for achieving complete remission after local consolidative therapy (LCT) in patients with advanced NSCLC.OBJECTIVEThis prospective nonrandomized trialwas conducted at a single center from June 3, 2020, to July 19, 2022, and included...
the germinal center B-cell-like (GCB) subtype and non-GCB subtype, characterized by different cells-of-origin (COO) and responses to chemotherapies or targeted therapies [67]. Both subtypes of DLBCL display established features of canonical SHM, while GCB cases exhibit ongoing SHM associated with...
Time-limited combination strategies have induced high objective response rates that have also proven to be durable in patients with CLL; however, these regimens have also been associated with high rates of toxicities and overtreatment of favorable-risk patients. Additionally, ...
the optimal conditioning regimen for older adults remains unknown as more intensive regimens tend to be associated with transplant-related mortality, while less intensive nonmyeloablative regimens have resulted historically in higher rates of disease relapse and progression,” Lori Muffly, MD, MS,...
17 In this study of patients with relapsed/refractory AML treated with first salvage chemotherapy, we showed that achievement of CR and MRD negativity by MFC are both independently associated with lower rates of relapse and superior RFS, even when accounting for subsequent HSCT. When hematologic ...
(94.5% vs 74.1%; HR, 0.20; 95% CI, 0.06-0.67; P =.002), and 13q deletion (95.3% vs 74.5%; HR, 0.20; 95% CI, 0.08-0.48; P <.001).Patients with mutant IGHV experienced similar outcomes with ibrutinib/venetoclax and FCR, with 3-year PFS rates of 94.3% and 88.8%, respe...
May 23, 2023 By Lindsay Fischer Article Fit patients with chronic lymphocytic leukemia achieved high undetectable minimal residual disease rates with frontline venetoclax combinations. Barbara Eichhorst, MD Frontline treatment with venetoclax (Venclexta) plus obinutuzumab (Gazyva), ...
including higher rates of sustained minimal residual disease (MRD) negativity daratumumab (Darzalex), bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) induction before autologus stem cell transplant (ASCT) followed by DR maintenance compared with standard induction with VRd,...